Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 16 tags : Positive save search
Exponential Demand for RFID Tags Positions Surgical Instrument Tracking Market to Surpass US$ 1,294.89 Mn
Published: 2022-02-16 (Crawled : 19:00) - prnewswire.com
STE | $204.05 -0.94% 140K
|
Health Technology
|
| O: -0.91%
H: 0.03%
C: -1.81%
ema one positive
PURA Positions Farmersville Hemp As A Global Brand Targeting $18 Billion Market
Published: 2022-02-16 (Crawled : 14:30) - globenewswire.com
ALKM | $0.0001 100.0% 16M
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
SPRO | $1.445 0.7% 58K
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: -5.69%
spr206 trial therapeutics phase 1 topline results positive topline phase 2 phase 3
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
SKYE | $12.83 -8.55% 79K
|
Transportation and Warehousing
|
| O: -2.11%
H: 33.85%
C: 28.62%
sbi-100 positive results 100 report positive bioscience results
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
SPRO | $1.445 0.7% 58K
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: -5.69%
spr206 treatment xin drug trial therapeutics phase 1 topline results positive topline infection negative iot set infections
Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)
Published: 2022-02-16 (Crawled : 13:00) - globenewswire.com
RYTM A | $39.975 -0.06% 180K
|
Health Technology
|
| O: -1.33%
H: 1.34%
C: -1.04%
als positive setmelanotide set syndros
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
BMY | $48.875 -0.24% 11M
|
Health Technology
|
| O: 0.0%
H: 0.91%
C: -0.25%
cardio trial mavacamten topline results positive topline phase 3
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.